Aging
Navigate
Submit an Article
Research Paper|Volume 9, Issue 11|pp 2334—2351

Expression of a novel CNPY2 isoform in colorectal cancer and its association with oncologic prognosis

Jianhong Peng1, Qingjian Ou1,2, Jian Guo3, Zhizhong Pan1, Rongxin Zhang1, Xiaojun Wu1, Yujie Zhao1, Yuxiang Deng1, Caixia Li4, Fulong Wang1, Liren Li1, Gong Chen1, Zhenhai Lu1, Peirong Ding1, Desen Wan1, Yujing Fang1,2
  • 1Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China
  • 2Department of Experimental Research, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China
  • 3Senboll Biotechnology Co., Ltd., Pingshan Bio-pharmacy Business Accelerator Unit 205, Shenzhen, Guangdong 518000, P. R. China
  • 4School of Mathematics and Computational Science, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China

* * Equal contribution

Received: September 24, 2017Accepted: November 3, 2017Published: November 13, 2017
https://doi.org/10.18632/aging.101324

Copyright: © 2017 Peng et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related mortality. Recently, we identified a novel biomarker, canopy fibroblast growth factor signaling regulator 2 (CNPY2) isoform2, and subsequently investigated its expression and prognostic value in CRC patients. We initially generated CNPY2 isoform2 monoclonal antibodies and examined CNPY2 isoform2 expression in CRC cell lines and tissues using quantitative real-time polymerase chain reaction, western blot and immunohistochemistry analyses. We found that CNPY2 isoform2 expression significantly increased in tumor cell lines and tissues compared with that in normal colon epithelial cells and tumor-adjacent normal tissues. Survival analysis indicated that patients with low CNPY2 isoform2 expression had poorer 5-year overall survival (OS) in both the training cohort (41.7% vs. 77.7%, P = 0.007) and validation cohort (47.1% vs. 78.8%, P = 0.002). In multivariable analysis, CNPY2 isoform2 was identified as a predictor of 5-year OS in both the training cohort [hazard ratio (HR) = 5.001; 95% confidence interval (CI) 2.156–11.598, P < 0.001) and validation cohort (HR= 2.443; 95% CI 1.197- 4.983, P = 0.014). In conclusion, CNPY2 isoform2 represents as a novel and valuable prognostic indicator for CRC patients, while the oncologic function of CNPY2 requires further study.